Keyphrases
Pancreatic Cancer
76%
Pancreatic Ductal Adenocarcinoma
64%
Acute Pancreatitis
42%
Pancreatitis
30%
Chronic Pancreatitis
30%
Pancreas
30%
NF-B
25%
RelA
21%
Gemcitabine
18%
Risk Factors
17%
Resectable Pancreatic Cancer
17%
Confidence Interval
13%
Metastatic Pancreatic Cancer
13%
Severe Acute Pancreatitis
13%
Tumor
12%
Odds Ratio
11%
Interleukin-6
11%
Acute Cholangitis
10%
Gemcitabine Plus Nab-paclitaxel
10%
Phase II Study
10%
Therapeutic Potential
10%
Pancreatic Intraepithelial Neoplasia (PanIN)
10%
Mouse Model
10%
Cancer Patients
9%
Inflammation
9%
Overall Survival
9%
Carbohydrate Antigen 19-9 (CA19-9)
9%
Olaparib
8%
Phase II Trial
8%
Autophagy
8%
Nab-paclitaxel
8%
Betacellulin
8%
Schwann Cells
8%
Autoimmune Pancreatitis
8%
Induction Chemotherapy
8%
Early Pancreatic Cancer
8%
COVID-19 Pandemic
8%
Pancreatic Carcinogenesis
8%
Metastasis
7%
Pancreatic Tumor
7%
Transcription Factor
7%
Boron Trichloride
7%
Macrophages
7%
Stent Therapy
7%
Inflammatory Cytokines
7%
Etiology
7%
Nuclear factor-B
7%
Cholangitis
6%
Acinar Cells
6%
Placebo
6%
Medicine and Dentistry
Pancreas Cancer
100%
Pancreas Adenocarcinoma
57%
Acute Pancreatitis
35%
Neoplasm
32%
Malignant Neoplasm
26%
Pancreatitis
25%
Chronic Pancreatitis
22%
Disease
20%
Gemcitabine
17%
Carisoprodol
16%
Carcinogenesis
14%
Chemotherapy
12%
Cholangitis
11%
Diagnosis
11%
Autophagy
11%
Overall Survival
11%
Odds Ratio
11%
Interleukin 6
11%
Acute Hemorrhagic Pancreatitis
10%
Cancer Cell
10%
Paclitaxel
9%
Metastatic Carcinoma
9%
Tumor Progression
9%
Placebo
9%
Pathogen
9%
Retrospective Study
9%
Surgery
8%
Cytokine
8%
Protein P53
8%
Olaparib
8%
Pancreatic Duct
8%
Autoimmune Pancreatitis
8%
COVID-19
8%
Phase II Trials
8%
Induction Chemotherapy
8%
Schwann Cell
8%
Germ Cell
8%
Serositis
7%
Pancreas Tumor
7%
Pancreas Adenoma
7%
Liver Metastasis
7%
Macrophage
7%
Cholestasis
6%
Endoscopic Retrograde Cholangiopancreatography
6%
Clinical Trial
6%
Arm
5%
Tissue Injury
5%
Survival Rate
5%
Signal Transduction
5%
Antibiotic Resistance
5%
